Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zevra Therapeutics filings document the regulatory record of a Nasdaq-listed, Delaware commercial-stage rare-disease therapeutics company. Recent Form 8-K reports furnish quarterly financial results and corporate updates, record leadership and principal financial officer changes, and disclose compensatory arrangements and inducement awards tied to executive appointments.
The filing record also includes definitive proxy materials covering board matters, executive compensation and shareholder voting items. Material-event filings describe the completed transfer of Zevra's SDX portfolio, including AZSTARYS and KP1077, under an asset purchase and settlement agreement, while Exchange Act disclosures identify the company's common stock on the Nasdaq Global Select Market.
Zevra Therapeutics Chief Legal & Compliance officer Rahsaan Thompson reported an open-market sale of 1,794 shares of common stock at $11.30 per share. After this transaction, he directly holds 48,125 shares. The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 01-08-2026, indicating it was pre-scheduled rather than a discretionary trade.
Zevra Therapeutics, Inc. reported a strong turnaround for the quarter ended March 31, 2026, driven by higher product sales and a major asset sale. Net revenue rose to $36.2 million, led by MIPLYFFA sales of $24.6 million and expanded access program revenue of $10.2 million. The company recorded a $43.3 million gain from selling its serdexmethylphenidate portfolio and related rights to Commave.
After factoring in this gain and one-time financing charges, Zevra generated net income of $37.9 million, compared with a loss a year earlier. It used the proceeds to fully repay approximately $63.1 million of long‑term debt, ending the quarter debt‑free with $95.6 million of cash and cash equivalents and total investments of $141.2 million. As of May 1, 2026, it had 59.1 million shares of common stock outstanding.
Zevra Therapeutics reported a strong turnaround in the first quarter of 2026, driven by higher product revenue and a major asset sale. Net revenue rose to $36.2 million, up 78% from Q1 2025, led by $24.6 million from MIPLYFFA and contributions from OLPRUVA, expanded access reimbursements, and AZSTARYS royalties.
The company recorded net income of $37.9 million, or $0.60 per diluted share, versus a loss a year earlier, largely reflecting a $43.3 million gain on the sale of its SDX portfolio and related proceeds of $40.5 million in the quarter. Zevra also prepaid the $63.1 million principal on its term loan, ending the period debt-free with $236.8 million in cash, cash equivalents and securities as of March 31, 2026.
Zevra Therapeutics reports that FMR LLC beneficially owned 3,211,876.51 shares of Common Stock, equal to 5.5% of the class as of 03/31/2026. The filing states FMR LLC holds sole dispositive power over 3,211,876.51 shares and discloses that other persons may have rights to dividends or sale proceeds. The filing was signed under power of attorney on behalf of FMR LLC and Abigail P. Johnson.
Zevra Therapeutics, Inc. is asking stockholders to elect two Class II directors, ratify Ernst & Young LLP as auditor for 2026, and approve phasing out its classified Board so all directors stand for annual elections beginning with the 2029 meeting.
The company highlights 2025 net revenue of $106.5 million, including $87.4 million from MIPLYFFA for Niemann-Pick disease type C, and GAAP diluted EPS of $1.35. Management reports more than 40% penetration of diagnosed U.S. NPC patients, 161 MIPLYFFA enrollment forms, and an Expanded Access Program serving 113 global patients.
Zevra also notes sale of a Rare Pediatric Disease Priority Review Voucher for $150 million, repayment of its term loan, and relocation of its headquarters to Boston. The Board emphasizes its largely independent composition, committee structure, and policies such as a clawback and prohibition on short-selling company stock.
Zevra Therapeutics reports 2025 commercial and corporate progress: $106.5 million in net revenue, including $87.4 million from MIPLYFFA® (arimoclomol), and recorded 161 MIPLYFFA enrollment forms. The company sold a Rare Pediatric Disease Priority Review Voucher for $150 million, expanded global access including an EAP for 113 patients, and advanced a Phase 3 trial with ~one-third enrolled. The 2026 Annual Meeting will be held virtually on June 4, 2026; the record date was April 6, 2026.
The Board recommends electing two Class II directors, ratifying EY as auditor, and approving declassification to annual director elections beginning after 2029.
Zevra Therapeutics Inc Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Common Stock and 0% beneficial ownership following an internal realignment. The filing explains certain Vanguard subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own those securities.
Zevra Therapeutics director John B. Bode exercised stock options to acquire 78,400 shares of common stock. On March 24, 2026, he exercised two option grants covering 39,200 shares each at exercise prices of $4.97 and $4.89 per share.
Following these exercises, Bode directly owns 123,400 shares of Zevra Therapeutics common stock. The transactions were reported as derivative exercises rather than open-market purchases or sales, indicating a shift from options-based compensation into outright share ownership.
Zevra Therapeutics, Inc. reported that its CFO, Justin A. Renz, received a grant of stock options to purchase 300,000 shares of common stock. The options have an exercise price of $9.55 per share, equal to the closing market price on March 18, 2026, and expire ten years after the grant date.
The award was made under Zevra’s 2023 Employment Inducement Award Plan and vests in four equal annual installments beginning on the first anniversary of the grant, subject to continued service. All underlying shares will vest in full immediately before a change of control, and vesting will be accelerated by 12 months if the CFO is terminated without cause or resigns for good reason.